Get In Touch

Cervical Cancer Diagnostic Tests Market: Snapshot

Advances in screening methods in cervical cytology along with increasing implementation of cervical screening programs, particularly in developing economies, are key to high growth momentum in the cervical cancer diagnostics tests market. Cervical cancer is associated with high mortality rate in such economies. Growing numbers of people who became newly infected with HIV in the past couple years have triggered the need for cervical cancer diagnostic tests. According to 2018 update by the WHO, cervical cancer is the fourth most frequent cancer in women, with a majority of mortality found in low- and middle-income countries in recent years. Efforts of governments in increasing access to screening programs are broadening the outlook of the market.

The global cervical cancer diagnostic tests market is expected to garner a healthy 6.10% CAGR during 2014 - 2020. The market stood at US$5.9 bn in 2013 and is projected to reach worth of US$8.9 bn by 2020-end.

Demand for Pap Tests Widespread for Detecting Potentially Precancerous Cells

The report segments the cancer diagnostic tests market on the basis of type of test and region. Major types of tests in cervical cancer are Pap smear tests, human papilloma virus (HPV) testing, colopscopy, and endocervical curettage (ECC) procedure, and an others segment. The others segment include loop electrosurgical excision procedure (LEEP) and cone biopsy. Of these, HPV testing and Pap tests have been popularly used in the diagnosis of cervical cancer for entirely different reasons. Pap tests have become popular in detecting potentially precancerous and cancerous processes, notably before more sensitive screening methods are used in cervical cancer patients.

The HPV segment is anticipate to expand at 8% CAGR between 2014 and 2020. The Pap smear tests segment is projected to clock a CAGR of more than 6% during 2014 – 2020. To a great deal, opportunities in the segment have thrived due to increased focus on early detection of cervical cancer. The tests are used in early detection of glandular cell abnormalities.

Improvement in diagnostic technology for detecting pre-cancerous lesions catalyzed demand for both types of tests in the cervical cancer diagnostic tests market. Growing incidences of cervical cancer and growing awareness about the disease will likely advance the market potential of colopscopy, ECC, and LEEP tests for diagnosing cervical cancer tests.

Increased Penetration of Screening Programs Cemented Growth in North America

The various regional markets for cervical cancer diagnostic tests are North America, Asia Pacific, Rest of the World, and Europe. Of all the regions, North America held the majority of share in 2013. Growing participation of regional populations in screening programs over the past few years had helped the regional market attain a prominent share. This has led to decreasing incidence of cervical cancer mortality. Further, substantial efforts have been made by public health systems to update guidelines for diagnosing cervical cancer.

Meanwhile, Asia Pacific is presenting large lucrative avenue. The demand for cervical cancer diagnostic tests has risen on the back of the growing initiatives by governments to reduce the heal burden and mortality rate due to cancer. The high unmet need for screening technologies in numerous countries is catalyzing the overall growth of this regional market.

Cervical cancer is a medical condition in which cells present in the lining of the cervix - gradually develop into pre-cancerous mass of cells that ultimately turn into cancerous tumors. Two major types of cervical cancers that are typically screened and diagnosed in women include adenocarcinoma and squamous cell carcinoma. At the same time, it has been observed that approximately 90% cases of cervical cancers are squamous cell carcinoma. Virtually, almost all the cases of cervical cancer cases are due to specific types of human papillomavirus and there are more than 100 different types of HPV virus present, of which nearly 40 are sexually transmitted. Among these, about 15 different types HPV viruses are considered as high-risk type or cancer causing. Today, cervical cancer is recognized to be one of the most common types of cancers affecting U.S. women and ranks 14th in frequency. Worldwide, cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 300,000 deaths annually.
 
This research report provides a detailed analysis of the global cervical cancer diagnostic tests market and helps in understanding the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. The executive summary provides detailed insights about the report and the market in general. It also contains a market snapshot, which provides a glimpse into the present scenario of the global cervical cancer diagnostic tests market. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report in order to deliver a thorough analysis of the overall competitive scenario of the global cervical cancer diagnostic tests market. 
 
The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations.
 
Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. 
 
The report concludes with the company profiles section and includes key information about the major players who are actively participating in this market. The company profiles included in the report are framed in terms of company overview, financial overview, business strategies, recent developments and product portfolio. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp.,

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

 
Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global Cervical Cancer Diagnostic Tests Market
2.2 Global Cervical Cancer Diagnostic Tests Market, by Type of Tests, 2013 (USD Million)
2.3 Comparative Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Market Overview
3.1 Introduction
3.2 Market Dynamics
      3.2.1 Market Drivers
              3.2.1.1 Rising prevalence rate of cervical cancer expected to boost market growth
              3.2.1.2 High incidence rate of HPV infections likely to drive the growth of the market
              3.2.1.3 Increasing cervical cancer screening awareness programs assisting in accelerating market growth
              3.2.1.4 Breakthrough products and technologies likely to fuel the growth of the market
      3.2.2 Market Restraints
              3.2.2.1 Lack of appropriate primary healthcare infrastructure to impede the growth of the market
              3.2.2.2 Low awareness hinders the growth of the market
      3.2.3 Market Opportunities
              3.2.3.1 Strengthening distribution network in emerging markets
3.3 Porter’s Five Forces Analysis
      3.3.1 Bargaining Power of Suppliers
      3.3.2 Bargaining Power of Buyers
      3.3.3 Threat of New Entrants
      3.3.4 Threat of Substitutes
      3.3.5 Competitive Rivalry
3.4 Market Attractiveness Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography
3.5 Heat Map Analysis for Cervical Cancer Diagnostic Tests Market, by Key Market Players
 
Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test
4.1 Introduction
      4.1.1 Global Cervical Cancer Diagnostic Tests Market Revenue, by Type of Tests, 2012 – 2020 (USD Million)
4.2 Pap Smear Tests
      4.2.1 Global Pap Smear Tests Market Revenue, 2012 – 2020 (USD Million)
4.3 Colposcopy
      4.3.1 Global Colposcopy Market Revenue, 2012 – 2020 (USD Million)
4.4 HPV Testing
      4.4.1 Global HPV Testing Market Revenue, 2012 – 2020 (USD Million)
4.5 Endocervical Curettage (ECC)
      4.5.1 Global Endocervical Curettage (ECC) Market Revenue, 2012 – 2020 (USD Million)
4.6 Others [Cone biopsy and Loop Electrosurgical Excision Procedure (LEEP)]
      4.6.1 Global Other Cervical Cancer Diagnostic Tests Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography
5.1 Overview
      5.1.1 Global Cervical Cancer Diagnostic Tests Market Revenue, by Geography, 2012-2020 (USD Million)
5.2 North America
      5.2.1 North America Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.3 Europe
      5.3.1 Europe Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.4 Asia Pacific
      5.4.1 Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 6 Recommendations
6.1 Success Strategies (Key Focus Areas)
      6.1.1 Gain Accreditation to Ensure Qualification to Participate in National Screening Programs across the Regions
      6.1.2 Target Emerging Markets of Asia Pacific and RoW
      6.1.3 Intensify Promotion and Training Programs for Healthcare Professionals
      6.1.4 Emphasis on Research and Development to come up with Innovative Solutions
 
Chapter 7 Company Profiles
7.1 Abbott Laboratories
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Becton, Dickinson and Company
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Hologic, Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 F. Hoffmann-La Roche Ltd.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Quest Diagnostics, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 QIAGEN N.V.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Femasys, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 Zilico Ltd.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Guided Therapeutics, Inc.
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments
7.10 OncoHealth Corp.
      7.10.1 Company Overview
      7.10.2 Financial Overview
      7.10.3 Product Portfolio
      7.10.4 Business Strategies
List of Tables
 
TABLE 1 Market Snapshot: Global Cervical Cancer Diagnostic Tests Market
TABLE 2 Global Cervical Cancer Diagnostic Tests Market Revenue, by Type of Tests, 2012 - 2020 (USD Million)
TABLE 3 Global Cervical Cancer Diagnostic Tests Market Revenue, by Geography, 2012 – 2020 (USD Million)
List of Figures
 
FIG. 1 Global Cervical Cancer Diagnostic Tests Market Segmentation
FIG. 1 Global Cervical Cancer Diagnostic Tests Market, by Type of Tests, 2013 (USD Million)
FIG. 2 Comparative Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography, 2013 & 2020 (Value %)
FIG. 3 Cervical Cancer Diagnostic Tests Market, Drivers and Restraints
FIG. 4 Porter’s Five Forces Analysis: Cervical Cancer Diagnostic Tests Market
FIG. 5 Market Attractiveness Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography
FIG. 6 Heat Map Analysis of Key Market Players for the Cervical Cancer Diagnostic Tests Market
FIG. 7 Global Pap Smear Tests Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Colposcopy Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 Global HPV Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global Endocervical Curettage (ECC) Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Other Cervical Cancer Diagnostic Tests Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 North America Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 13 Europe Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 14 Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 15 RoW Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 16 Abbott Laboratories: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 Becton, Dickinson & Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 18 Hologic, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Quest Diagnostics, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 QIAGEN N.V.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Guided Therapeutics, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Cervical Cancer Diagnostic Tests Market